[巴斯德梅里埃公司生产的“安可维”甲型肝炎疫苗的特性（现场临床试验结果）]
[Characteristics of "Avaxim" hepatitis A vaccine produced by the firm "Pasteur Merrier" (results of field clinical trials)].
作者信息
Gorbunov M A, Noskova A V, El'shina G A, Bektimirov T A, Pavlova L I, Aksenov L A, Ivanov A A
出版信息
Vopr Virusol. 2000 Jan-Feb;45(1):39-42.
Controlled field clinical trials of Avaxim vaccine from hepatitis A (Pasteur-Merrier-Connot) were carried out in adults and children aged 3-14 years to evaluate its reactogenicity and antigenic properties. The vaccine was weakly reactogenic both in adults and children. A single injection of the vaccine resulted after 1 month in the production of anti-HAV antibodies in 77.4% initially seronegative adults and 94.5% children. In adults the mean geometrical titer of antibodies was 95 mIU/ml and in children 165 mIU/ml, which was 5-8 times higher than the protective titer. These data recommend Avaxim vaccine for practical public health.
对来自巴斯德-梅里埃-康诺公司的甲型肝炎疫苗Avaxim进行了对照现场临床试验，试验对象为3至14岁的成人和儿童，以评估其反应原性和抗原特性。该疫苗在成人和儿童中反应原性都较弱。对疫苗进行单次注射后，1个月时，77.4%初始血清学阴性的成人和94.5%的儿童产生了抗甲型肝炎病毒抗体。成人抗体的平均几何滴度为95 mIU/ml，儿童为165 mIU/ml，比保护滴度高5至8倍。这些数据表明Avaxim疫苗可用于实际公共卫生。
Zotero 插件